https://scholars.lib.ntu.edu.tw/handle/123456789/582211
標題: | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update | 作者: | Liaw Y.-F. Leung N. Guan R. Lau G.K.K. Merican I. McCaughan G. Gane E. JIA-HORNG KAO Omata M. Chutaputti B.A. DING-SHINN CHEN Chien R.N. Cooksley G. Han K.H. Ichida T. Lai M.Y. Lesmana L. Piratvisuth T. Sarin S.K. Sollano J. Suh D.J. Yao G.B. Yeh C.T. Yokosuka O. |
關鍵字: | Adefovir; Chronic hepatitis B; Hepatic decompensation; Interferon; Lamivudine; Liver transplantation | 公開日期: | 2005 | 卷: | 25 | 期: | 3 | 起(迄)頁: | 472-489 | 來源出版物: | Liver International | 摘要: | Background/Aims: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update. Methods: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL. Results: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested. Conclusion: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment. ? Blackwell Munksgaard 2005. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-20444363583&doi=10.1111%2fj.1478-3231.2005.01134.x&partnerID=40&md5=e0bb4ad41886fa707188928d099e2cef https://scholars.lib.ntu.edu.tw/handle/123456789/582211 |
ISSN: | 1478-3223 | DOI: | 10.1111/j.1478-3231.2005.01134.x | SDG/關鍵字: | adefovir; adefovir dipivoxil; alanine aminotransferase; alpha interferon; clevudine; emtricitabine; entecavir; famciclovir; fialuridine; hepatitis B antibody; interleukin 12; lamivudine; lobucavir; peginterferon; peginterferon alpha2a; peginterferon alpha2b; ribavirin; telbivudine; tenofovir; thymosin; vidarabine; virus antigen; virus DNA; alanine aminotransferase blood level; antibiotic prophylaxis; antiviral activity; cancer chemotherapy; Chinese medicine; chronic hepatitis; clinical trial; comorbidity; depression; drug approval; drug dose regimen; drug efficacy; drug indication; drug mechanism; drug safety; drug substitution; fatigue; flu like syndrome; hepatitis B; Hepatitis B virus; hepatitis C; human; Human immunodeficiency virus infection; immunological tolerance; infection control; liver cirrhosis; liver transplantation; neutropenia; outcomes research; pathogenesis; patient care; patient monitoring; patient satisfaction; practice guideline; pregnancy; review; risk benefit analysis; thrombocytopenia; virus replication; Antiviral Agents; Asia; Australia; Hepatitis B, Chronic; Humans; New Zealand; Pacific Islands; Practice Guidelines |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。